Namandje Bumpus Sells 3,963 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Namandje Bumpus sold 3,963 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $3.18, for a total value of $12,602.34. Following the completion of the sale, the director owned 127,632 shares of the company’s stock, valued at $405,869.76. This trade represents a 3.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Namandje Bumpus also recently made the following trade(s):

• On Wednesday, June 3rd, Namandje Bumpus sold 4,386 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.54, for a total value of $15,526.44.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX opened at $3.17 on Wednesday. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $3.32 and its 200 day moving average price is $3.72. Recursion Pharmaceuticals, Inc. has a 52-week low of $2.77 and a 52-week high of $7.18. The firm has a market cap of $1.68 billion, a P/E ratio of -2.64 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. The company had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. Recursion Pharmaceuticals’s revenue was down 56.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.50) EPS. As a group, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RXRX. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. JPMorgan Chase & Co. decreased their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Finally, Bank of America cut their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.10.

Institutional Trading of Recursion Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. International Assets Investment Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at $31,000. Allworth Financial LP boosted its position in Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after acquiring an additional 4,403 shares during the period. Sequoia Financial Advisors LLC purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $41,000. IFP Advisors Inc grew its stake in Recursion Pharmaceuticals by 81.5% during the 3rd quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock valued at $51,000 after acquiring an additional 4,650 shares in the last quarter. Finally, NewEdge Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 28.1% in the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after purchasing an additional 2,428 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.